Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

AbbVie Accelerates Growth: £120M UK R&D Expansion & Innovative Oncology Breakthroughs Revealed

AbbVie’s Q3 filing shows steady growth, £120 million UK R&D expansion, and new bispecific antibody data slated for ASH, driving innovation and market momentum.

Dr. Michael Chen

05/11/2026, 15:20

3 minutes to read

AbbVie Boosts Global R&D, Drives Humira & Skyrizi Growth Ahead of Gene‑Therapy Expansion

AbbVie’s Q3 surge fuels growth in Humira, Skyrizi, and Jemperli, while a £120 m Oxford R&D hub expands global science, gene‑therapy partnerships, and regulatory alignment for faster, cost‑effective drug delivery.

Dr. Michael Chen

04/11/2026, 23:47

4 minutes to read

Kyowa Kirin Drives 50% Profit Surge in FY2026 First 9 Months with Biologics Growth

Kyowa Kirin’s first‑nine‑month fiscal 2026 results show a 50% profit jump driven by oncology sales, reduced R&D spending and new licensing income – a profitable, growth‑oriented outlook.

Dr. Michael Chen

04/11/2026, 14:24

4 minutes to read

Eurofins Scientific Executes Senior‑Management Share Transactions, Boosts Shares on Euronext‑Paris

Eurofins Scientific’s senior‑management share‑and‑warrant transactions, fully compliant with EU MAR, boost investor confidence and align with modest market gains.

Dr. Michael Chen

04/11/2026, 13:54

2 minutes to read

Regeneron Shares Hit 12‑Month High After Earnings Beat & Strong Antibody Sales

Regeneron shares hit a 12‑month high after beating earnings, driven by strong sales of COVID‑19 antibody Bebtelix and gene‑editing platform CRISPR‑Rx, signaling robust growth and investor optimism.

Dr. Michael Chen

02/11/2026, 14:39

3 minutes to read

How Kangmei Pharma Cut Revenue but Boosted Earnings by 600%

First‑9‑month review: Kangmei Pharma cuts revenue 11% yet slashes costs, boosts margins, and earns 600% higher profit thanks to asset sales, debt settlements, and disciplined cost control – but cash flow dips 30%. Click to see how it balances short‑…

Dr. Michael Chen

02/11/2026, 08:46

3 minutes to read

How Bayer’s US Court Win Boosts Share Price—What the Q3 Earnings Reveal

After a legal victory, Bayer AG’s share price rises—now investors await Q3 earnings for a clearer picture of risk‑adjusted growth and market sentiment.

Dr. Michael Chen

02/11/2026, 07:34

4 minutes to read

Eisai Drives Lecanemab Forward: 5‑Year Clarity AD Success Fuels Global Market Momentum

Explore how Eisai’s 5‑year Clarity AD data and real‑world LEADER results validate lecanemab’s sustained efficacy, safety and global market potential for early Alzheimer’s.

Dr. Michael Chen

01/11/2026, 12:53

4 minutes to read

Regeneron Outshines Forecasts, Boosts Immunology Growth with New Sanofi Deal

Regeneron’s latest quarter tops forecasts with $4.62B revenue, a $2.80 EPS beat, and a $1.5B Sanofi partnership, driving investor confidence in its immunology pipeline.

Dr. Michael Chen

01/11/2026, 08:59

4 minutes to read

Shionogi Boosts FY2026 Outlook With Strong First‑Half Results and Robust Pipeline

Shionogi lifts FY2026 outlook after strong first‑half, driven by antibiotic sales and a growing pipeline, boosting revenue, EPS and dividend prospects.

Dr. Michael Chen

31/10/2026, 09:42

4 minutes to read

Newer articles